

# A Polymorphism in the AMPK $\alpha$ 2 Subunit Gene Is Associated With Insulin Resistance and Type 2 Diabetes in the Japanese Population

Momoko Horikoshi,<sup>1</sup> Kazuo Hara,<sup>1,2,3</sup> Jun Ohashi,<sup>4</sup> Kazuaki Miyake,<sup>5</sup> Katsushi Tokunaga,<sup>4</sup> Chikako Ito,<sup>6</sup> Masato Kasuga,<sup>5</sup> Ryoza Nagai,<sup>2</sup> and Takashi Kadowaki<sup>1,3,7</sup>

AMP-activated protein kinase (AMPK) acts as a fuel gauge for glucose and lipid metabolism. The gene encoding the  $\alpha$ 2 isoform of the catalytic subunit of AMPK (*PRKAA2*) is located at one of the Japanese type 2 diabetes loci mapped by our previous genome scan (1p36-32). *PRKAA2* is, therefore, a good candidate gene for insulin resistance and type 2 diabetes. We screened all nine exons, their exon-intron boundaries, and the 5' and 3' flanking regions of *PRKAA2* to identify single nucleotide polymorphisms (SNPs), and we genotyped 192 type 2 diabetic patients and 272 nondiabetic subjects to assess possible associations between genotypes or haplotypes and type 2 diabetes. None of the 10 SNPs genotyped was associated with type 2 diabetes, but the haplotype analysis, consisting of six representative SNPs, revealed one haplotype, with the A (minor) allele for rs2051040 and a major allele for the other five SNPs, to be associated with type 2 diabetes ( $P = 0.009$ ). This finding was confirmed in two larger replication samples (657 case and 360 control subjects,  $P = 0.021$ ; and 356 case and 192 control subjects from the same area in Japan,  $P = 0.007$ ) and a significant  $P$  value was obtained in the joint haplotype analysis of all samples (1,205 case and 824 control subjects,  $P = 0.0001$ ). Furthermore, insulin resistance was associated with rs2051040 in nondiabetic subjects, and those with the A (minor) allele had a higher homeostasis model assessment of insulin resistance index than those who did not (initial control subjects [ $n = 272$ ],  $P = 0.002$ ; and joint replication control subjects [ $n = 552$ ],  $P = 0.037$ ). We speculate that the *PRKAA2* gene influences insulin resistance and susceptibility to type 2 diabetes in the

Japanese population. *Diabetes* 55:919–923, 2006

Insulin resistance has been well demonstrated to be a fundamental element in the etiology of type 2 diabetes. The molecular mechanisms and genetic factors involved in insulin resistance have been extensively investigated. AMP-activated protein kinase (AMPK) is an enzyme that is activated by physiological and pharmacological stimuli, including muscle contraction (1), the antidiabetic agent metformin (2), and adipokines, such as leptin (3) or adiponectin (4). It is a heterotrimeric protein composed of a catalytic subunit ( $\alpha$ ) and two regulatory subunits ( $\beta$  and  $\gamma$ ). The catalytic subunit  $\alpha$  has two isoforms ( $\alpha$ 1 and  $\alpha$ 2), and while the  $\alpha$ 1 subunit isoform is ubiquitously expressed, the  $\alpha$ 2 subunit isoform, *PRKAA2*, is predominantly found in skeletal muscle and liver. Activation of AMPK in skeletal muscle leads to increased glucose uptake and enhanced insulin sensitivity (5), whereas in the liver AMPK activation inhibits glucose production (6). These characteristics of AMPK make this enzyme one of the key regulators of insulin sensitivity and glucose homeostasis. While AMPK $\alpha$ 1<sup>-/-</sup> mice have no apparent metabolic defects, AMPK $\alpha$ 2<sup>-/-</sup> mice exhibit insulin resistance (7). Moreover, *PRKAA2* is located on 1p36-32 (8), which is reportedly linked to type 2 diabetes in the Japanese population (9). *PRKAA2* is therefore a good candidate for the susceptibility gene to insulin resistance and type 2 diabetes.

## RESEARCH DESIGN AND METHODS

To examine the association between SNPs in *PRKAA2* and type 2 diabetes, we first recruited 192 type 2 diabetic patients (123 men and 69 women, aged  $61.3 \pm 0.6$  years, and BMI  $24.1 \pm 0.2$  kg/m<sup>2</sup>) and 272 nondiabetic subjects (129 men and 143 women, aged  $69.1 \pm 0.5$  years, and BMI  $23.9 \pm 0.2$  kg/m<sup>2</sup>) as the initial study populations. To confirm these initial results, we also recruited 657 diabetic patients (421 men and 236 women, aged  $63.1 \pm 0.3$  years, and BMI  $24.6 \pm 0.2$  kg/m<sup>2</sup>) and 360 nondiabetic subjects (141 men and 219 women, aged  $69.6 \pm 0.3$  years, and BMI  $23.4 \pm 0.2$  kg/m<sup>2</sup>) to obtain replication samples. In both the initial and the replication sample sets, diabetic patients were randomly recruited among those attending the outpatient clinic of the Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo (Tokyo, Japan), and the nondiabetic subjects from those undergoing routine health check-ups at the Hiroshima Atomic Bomb Casualty Council Health Management Center (Hiroshima, Japan). To prevent stratification bias, another unrelated 356 diabetic patients (217 men and 139 women, aged  $63.1 \pm 0.5$  years, and BMI  $23.8 \pm 0.5$  kg/m<sup>2</sup>) and 192 control subjects (93 men and 99 women, aged  $69.9 \pm 0.4$  years, and BMI  $24.6 \pm 0.2$  kg/m<sup>2</sup>) were recruited from the same region and same facility in Hiroshima, Japan. The inclusion criteria for this study were described previously (10). All participants gave informed

From the <sup>1</sup>Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; the <sup>2</sup>Department of Clinical Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; the <sup>3</sup>Core Research for Evolution Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan; the <sup>4</sup>Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; the <sup>5</sup>Department of Clinical Molecular Medicine, Division of Diabetes and Digestive and Kidney Diseases, Graduate School of Medicine, University of Kobe, Kobe, Japan; the <sup>6</sup>Hiroshima Atomic Bomb Casualty Council Health Management Center, Hiroshima, Japan; and the <sup>7</sup>National Institute of Health and Nutrition, Tokyo, Japan.

Address correspondence and reprint requests to Takashi Kadowaki, Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: kadowaki-3im@h.u-tokyo.ac.jp.

Received for publication 7 June 2005 and accepted in revised form 14 November 2005.


M.H. and K.H. contributed equally to this work.

Additional information for this article can be found in an online appendix available at <http://diabetes.diabetesjournals.org>.

AMPK, AMP-activated protein kinase; HOMA, homeostasis model assessment; LD, linkage disequilibrium; SNP, single nucleotide polymorphism.

© 2006 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.



**FIG. 1.** *PRKAA2* gene structure and haplotype blocks. Structures of *PRKAA2* and SNPs analyzed in this study. Coding and untranslated regions of *PRKAA2* are represented by ■ and ▨, respectively. SNPs identified by sequencing are shown in boldface. Each circle indicates a cluster of SNPs with  $r^2 > 0.8$ .

consent, and the ethics committee of the University of Tokyo approved this study.

**Screening and genotyping of *PRKAA2*.** We screened all nine exons, including their exon-intron boundaries, 5' untranslated region, 3' untranslated region, and 2,000-bp upstream region of *PRKAA2* in 32 diabetic patients to detect new single nucleotide polymorphisms (SNPs). The primer sequences are available from the authors. SNPs were genotyped by direct sequencing. Sequencing reactions were performed with the BigDye terminator (Applied Biosystems, Foster City, CA) and resolved using an ABI 3700 automated DNA

sequencer (Applied Biosystems). The results were integrated using a Sequencher (Gene Codes, Ann Arbor, MI), and individual SNPs were manually genotyped. Ambiguous base identifications were genotyped twice. SNPs were identified based on the sequence reported in GenBank (*PRKAA2*: NT\_032977). **Statistical analysis.** Genotype or allele associations for each SNP with type 2 diabetes were tested by Fisher's exact test. Homeostasis model assessment (HOMA) of insulin resistance was calculated as described previously for the nondiabetic subjects (11) in the initial samples because insulin therapy or treatment with oral hypoglycemic agents for type 2 diabetes would presum-

**TABLE 1**  
Genotype and allele frequencies for SNPs in *PRKAA2* in case and control samples (initial samples)

SNP ID*	Distance from ATG†	Location	Genotype	Genotype frequency			Minor allele frequency		
				Case (n = 192)	Control (n = 272)	P value‡	Case/Control	P value§	Odds ratio (95% CI)
<b>-1439A&gt;T</b>	-1439	Promoter	AA	114 (0.59)	149 (0.55)	0.57	0.22/0.25	0.31	0.85 (0.62–1.16)
SNP1 rs2051040	31695	Intron 2	GG	64 (0.33)	106 (0.39)	0.38	0.41/0.37	0.16	1.21 (0.92–1.58)
			GA	95 (0.50)	129 (0.47)				
			AA	33 (0.17)	37 (0.14)				
rs2796492	31711	Intron 2	CC	77 (0.40)	85 (0.31)	0.14	0.37/0.42	0.11	0.80 (0.61–1.05)
			CT	87 (0.45)	143 (0.53)				
			TT	28 (0.15)	44 (0.16)				
rs2796493	31720	Intron 2	GG	76 (0.39)	83 (0.31)	0.12	0.37/0.43	0.07	0.78 (0.60–1.04)
			GA	88 (0.46)	142 (0.52)				
			AA	28 (0.15)	47 (0.17)				
SNP2 rs2796495	31919	Intron 2	GG	75 (0.39)	82 (0.30)	0.13	0.37/0.43	0.09	0.80 (0.60–1.04)
			GA	90 (0.47)	146 (0.54)				
			AA	27 (0.16)	44 (0.16)				
<b>46991G&gt;A</b>	46991	Exon 4	GG	134 (0.70)	176 (0.65)	0.50	0.17/0.20	0.24	0.81 (0.58–1.14)
			GA	52 (0.27)	85 (0.31)				
			AA	6 (0.03)	11 (0.04)				
SNP3 rs2143754	47801	Intron 4	TT	70 (0.36)	83 (0.30)	0.15	0.40/0.46	0.06	0.77 (0.59–1.01)
			TC	92 (0.48)	128 (0.47)				
			CC	30 (0.16)	61 (0.23)				
SNP4 rs1418442	48077	Intron 4	AA	110 (0.57)	144 (0.53)	0.60	0.24/0.26	0.48	0.89 (0.66–1.21)
			AG	73 (0.38)	116 (0.43)				
			GG	9 (0.05)	12 (0.04)				
SNP5 <b>rs932447</b>	59169	Intron 7	AA	113 (0.59)	155 (0.57)	0.81	0.22/0.22	0.83	1.04 (0.76–1.42)
			AG	73 (0.38)	110 (0.40)				
			GG	6 (0.03)	7 (0.03)				
SNP6 <b>rs3738568</b>	62531	3' UTR	TT	153 (0.80)	198 (0.73)	0.22	0.11/0.15	0.12	0.73 (0.49–1.08)
			TC	35 (0.18)	68 (0.25)				
			CC	4 (0.02)	6 (0.02)				

\*Newly identified SNPs are shown in boldface. †A of the start codon is counted as 1. P values for ‡genotype frequency and §allele frequency. UTR, untranslated region.

TABLE 2  
Haplotype analyses

Haplotype	Initial samples			Replication samples		
	Case frequency	Control frequency	Permutation <i>P</i> value	Case frequency	Control frequency	Permutation <i>P</i> value
SNPs* 1 2 3 4 5 6						
<i>n</i>	192	272		657	360	
G G T A A T	0.14	0.18	0.162	0.14	0.17	0.227
<b>A G T A A T</b>	0.38	0.29	<b>0.009</b>	0.36	0.32	<b>0.021</b>
G A C G G T	0.16	0.19	0.256	0.20	0.19	0.495
G A C A A C	0.08	0.11	0.096	0.12	0.12	0.481

Haplotype	Hiroshima samples			Joint (initial + replication+ Hiroshima) samples		
	Case frequency	Control frequency	Permutation <i>P</i> value	Case frequency	Control frequency	Permutation <i>P</i> value
SNPs* 1 2 3 4 5 6						
<i>n</i>	356	192		1,205	824	
G G T A A T	0.15	0.13	0.272	0.15	0.16	0.1175
<b>A G T A A T</b>	0.35	0.26	<b>0.007</b>	0.37	0.30	<b>0.0001</b>
G A C G G T	0.19	0.16	0.237	0.19	0.18	0.6447
G A C A A C	0.11	0.08	0.232	0.11	0.11	0.6643

\*SNP1 is equivalent to rs2051040, SNP2 to rs2796495, SNP3 to rs2143754, SNP4 to rs1418442, SNP5 to rs932447, and SNP6 to rs3738568. The total of the frequencies of the common haplotypes does not reach 1.0 because rare haplotypes with frequencies <0.05 were excluded. *P* values <0.05 are shown in boldface. Given the conservative Bonferroni correction, a *P* value <0.0125 (0.05 divided by four common haplotypes obtained from haplotype frequency estimation) is considered significant in the initial samples. In the replication samples, a *P* value <0.05 is considered significant.

ably alter their insulin levels. A multiple regression analysis was used to test for associations between SNPs and insulin resistance after adjustment for age, sex, and BMI. The statistical analyses were performed using JMP for Windows version 4.00 software (SAS Institute, Cary, NC). *P* values were corrected by Bonferroni adjustment, and a *P* value <0.005 (i.e., 0.05 divided by the total number of SNPs) was considered significant in the initial study. The statistical power was calculated based on a test for differences in proportions of alleles between case and control subjects (described in detail by Ohashi et al. [12]).

**Haplotype analysis.** To examine the linkage disequilibrium (LD) structure, pairwise LD, *D'*, and  $r^2$  between SNPs and haplotype frequencies were estimated via the method of maximum likelihood from two-locus genotype data using the E-M algorithm under the assumption of Hardy-Weinberg equilibrium (13). For the estimation of haplotype frequencies, we selected one of the SNPs as a tagging SNP from every set of SNPs with  $r^2 > 0.80$ . All haplotypes were jointly tested for association with disease status by performing a  $2 \times n\chi^2$  test of independence in a permutation procedure, where *n* indicates the number of haplotypes with a frequency >0. Individual haplotypes were also tested for association with disease status with a  $2 \times 2\chi^2$  test of independence in a permutation procedure. In the permutation procedure, to account for the variability introduced by the haplotype frequency estimation, significance was assessed by permuting case and control status and recalculating the test statistic 1,000 times for each of the sample sets and 10,000 times for the combined sample set. The above calculations were performed with SNPAnalyze V3.2 Pro software (Dynamcom, Yokohama, Japan).

## RESULTS AND DISCUSSION


We identified four SNPs by screening *PRKAA2*, two SNPs of which were also reported in the public database (Fig. 1). Adding 6 more SNPs available in the JSNP (Japanese Single Nucleotide Polymorphisms) database (available at <http://snp.ims.u-tokyo.ac.jp/>), a total of 10 SNPs were genotyped in the initial samples. All the polymorphisms were in Hardy-Weinberg equilibrium and had a minor allele frequency >5%. None of the SNPs was associated with type 2 diabetes (Table 1 and online appendix Tables 1–3 [available at <http://diabetes.diabetesjournals.org/>]). Neither the difference in genotype frequency nor that in allele frequency had any significant influence on susceptibility to type 2 diabetes.

The LD pattern and the *D'* and  $r^2$  values of the 192 diabetic patients providing the initial sample are shown in

Fig. 2. The six groups of SNPs with  $r^2$  values >0.8 and each of the tagging SNPs (SNPs 1–6) are shown in Figs. 1 and 2. All the haplotypes with frequencies >5% for the entire sample are shown in Table 2. A general  $2 \times n$  test for independence revealed a significant difference ( $P = 0.009$ ) in haplotype frequencies with a minor (A) allele for rs2051040 and a major allele for all the other SNPs (AGTAAT) between case and control samples. Other common haplotypes were not associated with type 2 diabetes. These results were confirmed in a larger replication sample with 657 diabetic patients and 360 nondiabetic subjects. The haplotype with the A (minor) allele for rs2051040 and a major allele for the other five SNPs was associated with type 2 diabetes ( $P = 0.021$ ) (Table 2). Even a genetically homogenous population, such as that of Iceland, has been reported to show substantial divergence in allele frequencies among geographical areas (14). Therefore, we further confirmed the association between the haplotype AGTAAT and type 2 diabetes in a third panel ( $P = 0.007$ ) (Table 2), for which we enrolled both 356 type 2 diabetic and 192 nondiabetic subjects from the same area of Japan (Hiroshima) to exclude the possibility that the associations with the haplotype were falsely obtained as a result of population stratification among subjects enrolled from different areas of Japan.

A joint analysis of the whole sample revealed a significant association between haplotype AGTAAT and type 2 diabetes ( $P = 0.0001$ ) (Table 2). The total of the frequencies of the common haplotypes is <1.0 because rare haplotypes with frequencies <0.05 were excluded. The complete set of all estimated haplotypes for the case and control subjects is shown in online appendix Table 4.

We next investigated whether the polymorphisms in *PRKAA2* were associated with insulin resistance, as assessed by HOMA of insulin resistance. The association was compared between subjects with and without the minor allele. Among the 10 SNPs investigated, only



	rs2051040 -1439A>T	rs2796492	rs2796493	rs2796495	46991G>A	rs2143754	rs1418442	rs932447	rs3738568	T2DM D', r <sup>2</sup>
SNP1 ; <u>rs2051040</u>	0.81	0.85	0.88	0.87	1.00	0.78	0.82	0.91	1.00	0-0.1
rs2796492	0.13	1.00	1.00	0.96	1.00	0.86	0.88	1.00	1.00	0.1-0.2
rs2796493	0.35	0.43	0.98	0.94	0.78	0.82	0.72	0.84	0.77	0.2-0.3
SNP2 ; <u>rs2796495</u>	0.37	0.43	0.93	0.99	0.78	0.83	0.78	0.86	0.79	0.3-0.4
46991G>A	0.36	0.40	0.87	0.94	0.75	0.84	0.74	0.80	0.79	0.4-0.5
SNP3 ; <u>rs2143754</u>	0.055	0.14	0.21	0.20	0.21	0.85	0.39	0.59	0.98	0.5-0.6
rs1418442	0.28	0.35	0.61	0.63	0.60	0.26	0.90	0.94	0.95	0.6-0.7
SNP4 ; <u>rs1418442</u>	0.59	0.17	0.24	0.27	0.26	0.01	0.33	0.96	0.89	0.7-0.8
SNP5 ; <u>rs932447</u>	0.81	0.21	0.31	0.33	0.30	0.03	0.36	0.57	1.00	0.8-0.9
SNP6 ; <u>rs3738568</u>	0.035	0.09	0.15	0.15	0.16	0.89	0.20	0.04	0.05	0.9-1.0

FIG. 2. Pairwise LD between SNPs. The lower left and upper right triangles indicate pairwise LD and r<sup>2</sup> and D' values, respectively, in 192 type 2 diabetic (T2DM) patients. Underlined SNPs are the tagging SNPs that represent all of the tested SNPs based on r<sup>2</sup> > 0.8.

rs2051040 was associated with insulin resistance. Subjects with the A (minor) allele for rs2051040 had a higher HOMA of insulin resistance than those without it (AA/AG vs. GG 1.95 ± 0.08 vs. 1.49 ± 0.10, regression coefficient = 0.18, P = 0.002). This finding was also confirmed in the joint replication samples (AA/AG vs. GG 1.83 ± 0.07 vs. 1.59 ± 0.09, regression coefficient = 0.099, P = 0.037). No other SNPs were associated with insulin resistance or any other diabetes-related quantitative traits, such as age, sex, BMI, fasting glucose, fasting insulin, HbA<sub>1c</sub>, and HOMA-β.

PRKAA2 is a good candidate for the susceptibility gene to insulin resistance and type 2 diabetes. We therefore focused on PRKAA2 and genotyped 10 SNPs spanning from the promoter region to the 3' untranslated region. Even though alleles with an odds ratio of 1.2–1.3 could be detected with 80% power for the total sample for allele frequencies of 0.2 and 0.4, which correspond to the commonly observed allele frequencies in this study, we were unable to find associations between any single polymorphisms and type 2 diabetes. However, one common haplotype with the A (minor) allele for rs2051040 and a major allele for all the other SNPs was associated with type 2 diabetes. To jointly test all common haplotypes for associations with disease status, we also used PHASE version 2.1, performing a case-control permutation test with the default setting. In agreement with the haplotype analysis using SNPalyze, haplotype analysis using PHASE software revealed a significant difference (P = 0.01) in haplotype frequencies between case and control subjects

(data not shown). Likewise, SNPalyze also revealed a significant difference (global P = 0.004) in a permutation test for differences in haplotype frequencies between case and control subjects. We therefore conclude that there is a significant difference in haplotype frequencies between case and control subjects and that this difference may be attributable to the haplotype AGTAAT, i.e., the haplotype with a minor (A) allele for rs2051040 and a major allele for all the other SNPs.

This intronic SNP rs2051040 alone was not associated with type 2 diabetes, but it was significantly associated with insulin resistance (P = 0.002), consistent with the known function of AMPK. The association was still significant even when the conservative Bonferroni adjustment was taken into account. Subjects with the A allele for rs2051040 had more marked insulin resistance, and a haplotype containing the A allele for rs2051040 was observed more frequently in case compared with control subjects. The initial results were further confirmed in the joint replication samples.

The risk haplotype frequency is quite close to the frequency of rs2051040 in the case subjects, for example 0.38 and 0.41 in the initial sample, but quite different, 0.29 and 0.37, respectively, in the control subjects. The A allele of rs2051040 is present on a rare haplotype, AGCAAT, whose frequency is higher in the control than in the case subjects, and the presence of this haplotype appears to be responsible for the discrepancy between the A allele of

rs2051040 and risk haplotype frequencies in the case and control subjects (online appendix Table 4).

We note two possible reasons why the association between rs2051040 and type 2 diabetes is evident in haplotypic, but not individual SNP, association analyses. One possibility is that an unidentified SNP, which is in LD with this risk haplotype but is in weaker LD with rs2051040, is the SNP actually causing type 2 diabetes. The other possibility is that rs2051040 and another SNP, contained in this risk haplotype, function in a coordinate manner to increase the risk of type 2 diabetes. The HapMap shows additional SNPs in the Chinese/Japanese sample between exon 1 and 2 of PRKAA2, where SNP finding was scarce in our study. An intronic SNP that is associated with type 2 diabetes in Japanese subjects may lie in this region. Further research to identify either the true causative SNP or as-yet-unidentified SNPs functioning in a coordinate manner with rs2051040 is needed.

#### ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid from the Pharmaceuticals and Medical Devices Agency (to T.K.); a Grant-in-Aid for Scientific Research on Priority Areas "Applied Genomics" from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to T.K.); and a Grant-in-Aid for the 21st Century COE Program (to R.N.).

We thank Ms. Y. Okada for technical assistance.

#### REFERENCES

- Mu J, Brozinick JT, Valladares O, Bucan M, Birnbaum MJ: A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. *Molec Cell* 7:1085–1094, 2001
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 108:1167–1174, 2001
- Minokoshi Y, Kim YB, Peroni OD, Fryer LGD, Müller C, Carling D, Kahn BB: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. *Nature* 415:339–343, 2002
- Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 8:1288–1295, 2002
- Musi N, Hayashi T, Fujii N, Hirshman MF, Witters LA, Goodyear LJ: AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. *Am J Physiol Endocrinol Metab* 280:E677–E684, 2001
- Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B: Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. *Diabetes* 54:1331–1339, 2005
- Viollet B, Andreelli F, Jorgensen SB, Perrin C, Flamez D, Mu J, Wojtaszewski JF, Schuit FC, Birnbaum M, Richter E, Burcelin R, Vaulont S: Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. *Biochem Soc Trans* 31:216–219, 2003
- Beri RK, Marley AE, See CG, Sopwith WF, Aguan K, Carling D, Scott J, Carey F: Molecular cloning, expression and chromosomal localisation of human AMP-activated protein kinase. *FEBS Lett* 356:117–121, 1994
- Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, Lecocour C, Vatin V, Durand E, Hara K, Okada T, Tobe K, Boutin P, Kadowaki T, Froguel P: Genome-wide search for type 2 diabetes in Japanese affected sibpairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. *Diabetes* 51:1247–1255, 2002
- Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes* 51:536–540, 2002
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419, 1985
- Ohashi J, Maruya E, Tokunaga K, Saji H: Power of association test for detecting minor histocompatibility gene causing graft-versus-host disease following bone marrow transplantation. *J Hum Genet* 48:502–507, 2003
- Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol Biol Evol* 5:921–927, 1995
- Helgason A, Yngvadottir B, Hrafnkelsson B, Gulcher J, Stefansson K: An Icelandic example of the impact of population structure on association studies. *Nat Genet* 37:90–95, 2005